Australia markets closed

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
139.08-4.30 (-3.00%)
As of 10:10AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close143.38
Open143.07
Bid141.16 x 1200
Ask141.44 x 1000
Day's range138.94 - 144.77
52-week range119.01 - 497.49
Volume1,171,338
Avg. volume7,177,714
Market cap55.32B
Beta (5Y monthly)1.70
PE ratio (TTM)4.09
EPS (TTM)34.02
Earnings date03 Aug 2022 - 08 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est220.00
  • Motley Fool

    Here's How Moderna Could Top $450 Again

    Moderna (NASDAQ: MRNA) shares have dropped 70% since their record high of more than $450 last August. The second reason has to do with Moderna specifically. The company's only commercialized product right now is the coronavirus vaccine, so investors worry about earnings if vaccine demand drops in a post-pandemic world.

  • Motley Fool

    Why Pfizer Looks Better Than Moderna as a Long-Term Buy

    For a stock to be a strong long-term buy, investors need to have confidence that its business will be able to grow indefinitely. Both Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are examples of companies that continue to thrive today due to the pandemic with their highly successful COVID-19 vaccines generating billions in sales for their respective companies. COVID-19 revenue has resulted in surging revenue for Pfizer.

  • Motley Fool

    2 Top Healthcare Stocks to Buy for the Long Haul

    Moderna (NASDAQ: MRNA) and Repligen (NASDAQ: RGEN) are two companies that have seen their stock prices decrease even as they posted positive business results. While Moderna may have been known to some investors prior to the pandemic, the biotech company has become a household name as it was able to bring to market its highly successful vaccine for COVID-19. Prior to this, Moderna had nothing commercially available, so the sales growth over the past year-plus is from a base of zero revenue.